Induction of the angiogenic factor VEGF in the uterus by the antiprogestin onapristone

Cancer Letters

Volumn 156, Issue 1, 2000, Pages 101-107

  Hyder, Salman M ^a   Chiappetta, Constance ^a   Stancel, George M ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

Angiogenesis; Antiprogestin; Estrogen receptor; Onapristone; Vascular endothelial growth factor; ZK 98,299

Indexed keywords

ANTIGESTAGEN; ESTROGEN RECEPTOR; FULVESTRANT; MIFEPRISTONE; ONAPRISTONE; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; FEMALE; NONHUMAN; PRIORITY JOURNAL; RAT; UTERUS;

ANIMALS; ENDOTHELIAL GROWTH FACTORS; ESTRADIOL; FEMALE; GONANES; HORMONE ANTAGONISTS; LYMPHOKINES; MIFEPRISTONE; PROGESTINS; PROTO-ONCOGENE PROTEINS C-FOS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RNA, MESSENGER; UTERUS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0034257194     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3835(00)00448-1     Document Type: Article

References (34)

1. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat. Med. 1:1995;27-31.
2. Marme D. Tumor angiogenesis - the pivotal role of vascular endothelial growth factor. World J. Urol. 14:1996;166-174.
3. Cullinan-Bove K., Koos R.D. Vascular endothelial growth factor/vascular permeability factor expression in the rat uterus: Rapid stimulation by estrogen correlates with estrogen-induced increases in uterine capillary permeability and growth. Endocrinology. 133:1993;829-837.
4. Nakamura J., Savinov A., Lu Q., Brodie A. Estrogen regulates vascular endothelial growth permeability factor expression in 7,12-dimethylbenz(a)anthracene-induced rat mammary tumors. Endocrinology. 137:1996;5589-5596.
5. Hyder S.M., Stancel G.M., Chiappetta C., Murthy L., Boettgertong H.L., Makela S. Uterine expression of vascular endothelial growth factor is increased by estradiol and tamoxifen. Cancer Res. 56:1996;3954-3960.
6. Greb R.R., Heikinheimo O., Williams R.F., Hodgen G.D., Goodman A.L. Vascular endothelial growth factor in primate endometrium is regulated by oestrogen-receptor and progesterone-receptor ligands in vivo. Hum. Reprod. 12:1997;1280-1292.
7. Huang J.C., Liu D.Y., Dawood M.Y. The expression of vascular endothelial growth factor isoforms in cultured human endometrial stromal cells and its regulation by 17β-oestradiol. Mol. Hum. Reprod. 4:1998;603-607.
8. Charnock-Jones D.S., Sharkey A.M., Rajput-Williams J., Burch D., Schofield J.P., Fountain S.A., Boocock C.A., Smith S.K. Identification and localization of alternately spliced mRNAs for vascular endothelial growth factor in human uterus and estrogen regulation in endometrial carcinoma cell lines. Biol. Reprod. 48:1993;1120-1128.
9. Hyder S.M., Murthy L., Stancel G.M. Progestin regulation of vascular endothelial growth factor in human breast cancer cells. Cancer Res. 58:1998;392-395.
10. Ruohola J.K., Valve E.M., Karkkainen M.J., Joukov V., Alitalo K., Harkonen P.L. Vascular endothelial growth factors are differentially regulated by steroid hormones and antiestrogens in breast cancer cells. Mol. Cell. Endocrinol. 149:1999;29-40.
11. Hyder S.M., Chiappetta C., Murthy L., Stancel G.M. Selective inhibition of estrogen-regulated gene expression in vivo by the pure antiestrogen ICI 182,780. Cancer Res. 57:1997;2547-2549.
12. Chirgwin J.M., Przybyla A.E., MacDonald R.J., Rutter W.J. Isolation of biologically active ribonucleic acids from sources enriched in ribonucleases. Biochemistry. 18:1979;5294-5299.
13. Loose-Mitchell D.S., Chiappetta C., Stancel G.M. Estrogen regulation of c-fos messenger ribonucleic acid. Mol. Endocrinol. 2:1988;946-951.
14. Hyder S.M., Chiappetta C., Stancel G.M. Synthetic estrogen 17α-ethinyl estradiol induces pattern of uterine gene expression similar to endogenous estrogen 17β-estradiol. J. Pharmacol. Exp. Ther. 290:1999;740-747.
15. Herrmann W., Wyss R., Riondel A., Philibert D., Teutsch G., Sakiz E., Baulieu E.E. The effects of an antiprogesterone steroid in women: interruption of the menstrual cycle and of early pregnancy. C.R. Seances Acad. Sci. III. 294:1982;933-938.
16. Kirkland J.L., Murthy L., Stancel G.M. Progesterone inhibits estrogen-induced increases in c-fos mRNA levels in the uterus. Recent Prog. Horm. Res. 48:1993;477-480.
17. Hyder S.M., Chiappetta C., Stancel G.M. Triphenylethylene antiestrogens induce uterine vascular endothelial growth factor expression via their partial estrogen agonist activity. Cancer Lett. 120:1997;165-171.
18. Beier H.M., Spitz I.M. Progesterone Antagonists in Reproductive Medicine and Oncology. 1994;Oxford University Press, Oxford.
19. Gass E.K., Leonhardt S.A., Nordeen S.K., Edwards D.P. The antagonists RU-486 and ZK 98,299 stimulate progesterone receptor binding to deoxyribonucleic acid in vitro and in vivo, but have distinct effects on receptor conformation. Endocrinology. 139:1998;1905-1919.
20. Sartorius C.A., Tung L., Takimoto G.S., Horwitz K.B. Antagonist-occupied human progesterone receptors bound to DNA are functionally switched to transcriptional agonists by cAMP. J. Biol. Chem. 268:1993;9262-9266.
21. Hyder S.M., Stancel G.M. Regulation of angiogenic growth factors in the female reproductive tract by estrogens and progestins. Mol. Endocrinol. 13:1999;806-811.
22. Hyder S.M., Stancel G.M. Regulation of VEGF by sex-steroids in female reproductive tract. Histol. Histopathol. 15:2000;325-334.
23. Rumpel E., Michna H., Kuhnel W. Morphology of the rat uterus after long-term treatment with progesterone antagonists. Anat. Anz. 175:1993;141-149.
24. Bigsby R.M., Young P.C.M. Estrogenic effects of the antiprogestin onapristone (ZK98,299) in the rodent uterus. Am. J. Obstet. Gynecol. 171:1994;188-194.
25. Norris J.D., Fan D.J., Wagner B.L., McDonnell D.P. Identification of the sequences within the human complement 3 promoter required for estrogen responsiveness provides insight into the mechanism of tamoxifen mixed agonist activity. Mol. Endocrinol. 10:1996;1605-1616.
26. Isaacson K.B., Xu Q., Lyttle C.R. The effect of estradiol on the production and secretion of complement component 3 by the rat uterus and surgically induced endometriotic tissue. Fertil. Steril. 55:1991;395-402.
27. Snyder B.W., Reel J.R., Winneker R.C., Batzold F.H., Potts G.O. Effect of epostane, ZK 98299, and ZK 98734 on the interruption of pregnancy in the rat. Biol. Reprod. 40:1989;549-554.
28. Jeng M.H., Jordan V.C. Growth stimulation and differential regulation of transforming growth factor-β 1 (TGF β 1), TGF β 2, and TGF β 3 messenger RNA levels by norethindrone in MCF-7 human breast cancer cells. Mol. Endocrinol. 5:1991;1120-1128.
29. Jeng M.H., Parker C.J., Jordan V.C. Estrogenic potential of progestins in oral contraceptives to stimulate human breast cancer cell proliferation. Cancer Res. 52:1992;6539-6546.
30. Catherino W.H., Jeng M.H., Jordan V.C. Norgestrel and gestodene stimulate breast cancer cell growth through an oestrogen receptor mediated mechanism. Br. J. Cancer. 67:1993;945-952.
31. Jeng M.H., Langan-Fahey S.M., Jordan V.C. Estrogenic action of RU-486 in hormone responsive MCF-7 human breast cancer cells. Endocrinology. 132:1993;2622-2630.
32. Chwalisz K., Stockemann K., Fritzemeier K-H., Fuhrmann U. Modulation of oestrogenic effects by progesterone antagonists in the rat uterus. Hum. Reprod. Update. 4:1998;570-583.
33. 3H-labeled RU 38486: characterization of binding sites in human uterine cytosol. J. Clin. Chem. Clin. Biochem. 23:1985;265-276.
34. Elger W., Beier S., Chwalisz K., Fahnrich M., Hasan S.H., Henderson D., Neef G., Rohde R. Studies on the mechanisms of action of progesterone antagonists. J. Steroid Biochem. 25:1986;835-845.